UCB, BIOGEN TO DEVELOP ORAL MULTIPLE SCLEROSIS THERAPY

Biogen Idec Inc. and Belgian biopharmaceutical company UCB after Monday's closing bell said they will develop and market CDP323 for the treatment of relapsing-remitting multiple sclerosis. CDP323 is a molecule alpha4-integrin inhibitor that is expected to enter Phase II clinical trials next year. Easy Bourse (http://www.easybourse.com/Website/dynamic/News.php?NewsID=65706&lang=fra&NewsRubrique=2)